Author

Stefan O Ciurea

Professor, University of California, Irvine - Cited by 10,835

Biography

 Stefan O Ciurea is  M.D., Associate Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX his research interest are Mismatched related donors are a potential source of stem cells for virtually all patients who lack a matched sibling or unrelated donor. Expanding the use of stem cells from mismatched relatives by identifying barriers against successful transplantation, optimizing conditioning regimens, separating the graft-versus-tumor effect from graft-versus-host disease and incorporating novel strategies to enhance anti-tumor immunity, like the use of cellular therapy, represents a priority of my research.
Title
Cited by
Year
Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis
SR Goldsmith, MB Abid, JJ Auletta, A Bashey, A Beitinjaneh, P Castillo, ...Blood, The Journal of the American Society of Hematology 137 (23), 3291-3305, 2021202
68
2021
Decrease post-transplant relapse using donor-derived expanded NK-cells
SO Ciurea, P Kongtim, D Soebbing, P Trikha, G Behbehani, G Rondon, ...Leukemia 36 (1), 155-164, 2022202
38
2022
Treatment of allosensitized patients receiving allogeneic transplantation
SO Ciurea, MM Al Malki, P Kongtim, J Zou, FM Aung, G Rondon, J Chen, ...Blood advances 5 (20), 4031-4043, 2021202
24
2021
Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis
M Hamadani, AK Gopal, M Pasquini, S Kim, X Qiu, S Ahmed, A Lazaryan, ...Blood advances 6 (2), 486-494, 222
20
2022
Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD
RS Mehta, R Bassett, G Rondon, BJ Overman, UR Popat, CM Hosing, ...Bone marrow transplantation 56 (6), 1316-1324, 2021202
15
2021
Vedolizumab for steroid refractory lower gastrointestinal tract graft-versus-host disease
RS Mehta, RM Saliba, A Jan, TL Shigle, E Wang, Y Nieto, SO Ciurea, ...Transplantation and Cellular Therapy 27 (3), 272. e1-272. e5, 2021202
14
2021
Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation
SA Srour, A Olsonr, SO Ciurear, P Desair, Q Bashirr, B Oranr, P Boser, ...Haematologica 106 (7), 1988, 2021202
13
2021
Eltrombopag for post-transplantation thrombocytopenia: results of phase II randomized, double-blind, placebo-controlled trial
S Ahmed, Q Bashir, R Bassett, MYC Poon, B Valdez, S Konoplev, ...Transplantation and Cellular Therapy 27 (5), 430. e1-430. e7, 2021202
12
2021
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
D Kegyes, C Constantinescu, L Vrancken, L Rasche, C Gregoire, B Tigu, ...Journal of Hematology & Oncology 15 (1), 78, 2022202
11
2022
Bone marrow versus peripheral blood grafts for haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide
RS Mehta, RM Saliba, LC Alsfeld, JL Jorgensen, SA Wang, P Anderlini, ...Transplantation and Cellular Therapy 27 (12), 03. e1-03. e13, 2021202
10
2021
Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells
T Cai, A Gouble, KL Black, A Skwarska, AS Naqvi, D Taylor, M Zhao, ...Nature communications 13 (1), 2228, 2022202
10
2022
Incidence and impact of community respiratory viral infections in post‐transplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis and …
CM Mulroney, MB Abid, A Bashey, RF Chemaly, SO Ciurea, M Chen, ...British journal of haematology 14 (1), 145-157, 2021202
9
2021
Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era
MV Shah, RM Saliba, A Varma, SO Ciurea, B Oran, A Olson, P Bose, ...British journal of haematology 193 (5), 1004-1008, 2021202
6
2021
Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome
B Oran, RM Saliba, RS Mehta, AM Alousi, D Marin, BC Valdez, J Chen, ...Cancer 127 (10), 1598-105, 2021202
6
2021
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
K Menghrajani, A Gomez-Arteaga, R Madero-Marroquin, MJ Zhang, ...Blood advances 6 (3), 828-847, 2022202
5
2022
Number of HLA-mismatched eplets is not associated with major outcomes in haploidentical transplantation with post-transplantation cyclophosphamide: A Center for International …
J Zou, T Wang, M He, YT Bolon, SM Gadalla, SGE Marsh, M Kuxhausen, ...Transplantation and Cellular Therapy 28 (2), 107. e1-107. e8, 2022202
5
2022
Refined HLA-DPB1 mismatch with molecular algorithms predicts outcomes in hematopoietic stem cell transplantation
J Zou, P Kongtim, B Oran, V Kosmoliaptsis, Y Carmazzi, J Ma, L Li, ...haematologica 107 (4), 844, 2022202
5
2022
Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation
P Koller, RM Saliba, C Ledesma, G Rondon, U Popat, A Alousi, R Mehta, ...Bone marrow transplantation 6 (7), 1746-1749, 2021202
5
2021
Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis
RM Saliba, AM Alousi, J Pidala, M Arora, SR Spellman, MT Hemmer, ...Transplantation and cellular therapy 28 (10), 681-693, 2022202
5
2022
Myeloablative fractionated busulfan with fludarabine in older patients: long term disease-specific outcomes of a prospective phase II clinical trial
RS Mehta, R Bassett, J Chen, BC Valdez, J Kawedia, AM Alousi, ...Transplantation and Cellular Therapy 27 (11), 913. e1-913. e12, 2021202
4
2021

Referred From: https://scholar.google.com/citations?user=8OlpDy4AAAAJ&hl=en

Cited by
Citations 10835
h-index 51
i10-index 157
Recommended Journals
Open Access Journals